As of March 31, 2023, cash and cash equivalents were $33.6 million, compared to $20.5 million on March 31, 2022. These funds are expected to provide the Company with sufficient capital to execute its current planned expenditures through the key milestones of the ABILITY study and through calendar Q3 2024 based on its current plans and projections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDNA: